drug · small molecule
vimseltinib
Marketedupdated 3mo agoby Ono Pharmaceutical Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for tenosynovial giant cell tumor and 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying vimseltinib
- phase1Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
- phase1Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
- phase3Study of Vimseltinib for Tenosynovial Giant Cell Tumor
- phase1Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
- phase1Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
- phase2Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
- phase2A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 14, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (30)
- Apr 30, 2045formulationUS 12509443
- Apr 30, 2045formulationUS 12509443
- Apr 30, 2045formulationUS 12509443
- Dec 6, 2044formulationUS 12447149
- Dec 6, 2044formulationUS 12447149
- Dec 6, 2044formulationUS 12447149
- Dec 6, 2044compositionUS 12528787
- Dec 6, 2044compositionUS 12528787
- Dec 6, 2044compositionUS 12528787
- Dec 6, 2044formulationUS 12551483
- Dec 6, 2044formulationUS 12551483
- Dec 6, 2044formulationUS 12551483
- Feb 3, 2040method-of-use (U-4145)US 11103507
- Feb 3, 2040method-of-use (U-4145)US 11103507
- Feb 3, 2040method-of-use (U-4145)US 11103507
- Feb 3, 2040method-of-use (U-4145)US 11679110
- Feb 3, 2040method-of-use (U-4145)US 11679110
- Feb 3, 2040method-of-use (U-4145)US 11679110
- Dec 23, 2039method-of-use (U-4145)US 12285430
- Dec 23, 2039method-of-use (U-4145)US 12285430
- Dec 23, 2039method-of-use (U-4145)US 12285430
- Dec 23, 2039method-of-use (U-4145)US 12485120
- Dec 23, 2039method-of-use (U-4145)US 12485120
- Dec 23, 2039method-of-use (U-4145)US 12485120
- Dec 23, 2039method-of-use (U-4145)US 12582655
- Dec 23, 2039method-of-use (U-4145)US 12582655
- Dec 23, 2039method-of-use (U-4145)US 12582655
- Mar 14, 2034compositionUS 9181223
- Mar 14, 2034compositionUS 9181223
- Mar 14, 2034compositionUS 9181223
FDA exclusivities (3)
- Feb 14, 2030NCENew Chemical Entity (5y)3.5y
- Feb 14, 2030NCENew Chemical Entity (5y)3.5y
- Feb 14, 2030NCENew Chemical Entity (5y)3.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that